BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30549430)

  • 1. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
    Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
    Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
    Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus: evasive maneuvers in the development of PTLD.
    Snow AL; Martinez OM
    Am J Transplant; 2007 Feb; 7(2):271-7. PubMed ID: 17229074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus, rapamycin, and host immune responses.
    Krams SM; Martinez OM
    Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.
    Nepomuceno RR; Balatoni CE; Natkunam Y; Snow AL; Krams SM; Martinez OM
    Cancer Res; 2003 Aug; 63(15):4472-80. PubMed ID: 12907620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
    Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
    Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
    Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival.
    Harris-Arnold A; Arnold CP; Schaffert S; Hatton O; Krams SM; Esquivel CO; Martinez OM
    Am J Transplant; 2015 Nov; 15(11):2814-24. PubMed ID: 26147452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
    Reddy N; Rezvani K; Barrett AJ; Savani BN
    Biol Blood Marrow Transplant; 2011 May; 17(5):591-7. PubMed ID: 20732435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
    Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
    Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
    Robert A; Pujals A; Favre L; Debernardi J; Wiels J
    Mol Oncol; 2020 Oct; 14(10):2520-2532. PubMed ID: 32623836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.
    White RE; Rämer PC; Naresh KN; Meixlsperger S; Pinaud L; Rooney C; Savoldo B; Coutinho R; Bödör C; Gribben J; Ibrahim HA; Bower M; Nourse JP; Gandhi MK; Middeldorp J; Cader FZ; Murray P; Münz C; Allday MJ
    J Clin Invest; 2012 Apr; 122(4):1487-502. PubMed ID: 22406538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
    Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.